

Brian T Fisher

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6331188/publications.pdf>

Version: 2024-02-01

149
papers

4,442
citations

186265

28
h-index

118850

62
g-index

153
all docs

153
docs citations

153
times ranked

5437
citing authors

#	ARTICLE	IF	CITATIONS
1	Revision and Update of the Consensus Definitions of Invasive Fungal Disease From the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium. <i>Clinical Infectious Diseases</i> , 2020, 71, 1367-1376.	5.8	1,429
2	Guideline for the Management of Fever and Neutropenia in Children With Cancer and Hematopoietic Stem-Cell Transplantation Recipients: 2017 Update. <i>Journal of Clinical Oncology</i> , 2017, 35, 2082-2094.	1.6	337
3	Effect of Levofloxacin Prophylaxis on Bacteremia in Children With Acute Leukemia or Undergoing Hematopoietic Stem Cell Transplantation. <i>JAMA - Journal of the American Medical Association</i> , 2018, 320, 995.	7.4	136
4	Galactomannan, β -D-Glucan, and Polymerase Chain Reaction–Based Assays for the Diagnosis of Invasive Fungal Disease in Pediatric Cancer and Hematopoietic Stem Cell Transplantation: A Systematic Review and Meta-Analysis. <i>Clinical Infectious Diseases</i> , 2016, 63, 1340-1348.	5.8	123
5	Association of Social Distancing, Population Density, and Temperature With the Instantaneous Reproduction Number of SARS-CoV-2 in Counties Across the United States. <i>JAMA Network Open</i> , 2020, 3, e2016099.	5.9	115
6	Bronchoalveolar Lavage and Lung Biopsy in Patients With Cancer and Hematopoietic Stem-Cell Transplantation Recipients: A Systematic Review and Meta-Analysis. <i>Journal of Clinical Oncology</i> , 2015, 33, 501-509.	1.6	108
7	A Prospective, International Cohort Study of Invasive Mold Infections in Children. <i>Journal of the Pediatric Infectious Diseases Society</i> , 2015, 4, 313-322.	1.3	86
8	Guideline for Antibacterial Prophylaxis Administration in Pediatric Cancer and Hematopoietic Stem Cell Transplantation. <i>Clinical Infectious Diseases</i> , 2020, 71, 226-236.	5.8	84
9	Risk Factors for Invasive Fungal Disease in Pediatric Cancer and Hematopoietic Stem Cell Transplantation: A Systematic Review. <i>Journal of the Pediatric Infectious Diseases Society</i> , 2018, 7, 191-198.	1.3	83
10	Bortezomib with standard chemotherapy for children with acute myeloid leukemia does not improve treatment outcomes: a report from the Children’s Oncology Group. <i>Haematologica</i> , 2020, 105, 1879-1886.	3.5	83
11	Association of Acute Kidney Injury With Concomitant Vancomycin and Piperacillin/Tazobactam Treatment Among Hospitalized Children. <i>JAMA Pediatrics</i> , 2017, 171, e173219.	6.2	72
12	Classification of treatment-related mortality in children with cancer: a systematic assessment. <i>Lancet Oncology</i> , The, 2015, 16, e604-e610.	10.7	69
13	Effect of Caspofungin vs Fluconazole Prophylaxis on Invasive Fungal Disease Among Children and Young Adults With Acute Myeloid Leukemia. <i>JAMA - Journal of the American Medical Association</i> , 2019, 322, 1673.	7.4	67
14	Clinical Practice Guideline for Systemic Antifungal Prophylaxis in Pediatric Patients With Cancer and Hematopoietic Stem-Cell Transplantation Recipients. <i>Journal of Clinical Oncology</i> , 2020, 38, 3205-3216.	1.6	63
15	Role of Molecular Biomarkers in the Diagnosis of Invasive Fungal Diseases in Children. <i>Journal of the Pediatric Infectious Diseases Society</i> , 2017, 6, S32-S44.	1.3	62
16	Trends in <i>Clostridium difficile</i> Infection and Risk Factors for Hospital Acquisition of <i>Clostridium difficile</i> among Children with Cancer. <i>Journal of Pediatrics</i> , 2013, 163, 699-705.e1.	1.8	61
17	A Multicenter Consortium to Define the Epidemiology and Outcomes of Inpatient Respiratory Viral Infections in Pediatric Hematopoietic Stem Cell Transplant Recipients. <i>Journal of the Pediatric Infectious Diseases Society</i> , 2018, 7, 275-282.	1.3	53
18	Diagnostic Imaging and Invasive Fungal Diseases in Children. <i>Journal of the Pediatric Infectious Diseases Society</i> , 2017, 6, S22-S31.	1.3	52

#	ARTICLE	IF	CITATIONS
19	Efficacy of antibiotic prophylaxis in patients with cancer and hematopoietic stem cell transplantation recipients: A systematic review of randomized trials. <i>Cancer Medicine</i> , 2019, 8, 4536-4546.	2.8	52
20	T2Candida Provides Rapid and Accurate Species Identification in Pediatric Cases of Candidemia. <i>American Journal of Clinical Pathology</i> , 2016, 145, 858-861.	0.7	50
21	Accuracy of Adverse Event Ascertainment in Clinical Trials for Pediatric Acute Myeloid Leukemia. <i>Journal of Clinical Oncology</i> , 2016, 34, 1537-1543.	1.6	47
22	Children's Oncology Group Trial AALL1231: A Phase III Clinical Trial Testing Bortezomib in Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia and Lymphoma. <i>Journal of Clinical Oncology</i> , 2022, 40, 2106-2118.	1.6	45
23	Unintended consequences of evolution of the Common Terminology Criteria for Adverse Events. <i>Pediatric Blood and Cancer</i> , 2019, 66, e27747.	1.5	40
24	Galactomannan Antigen Testing for Diagnosis of Invasive Aspergillosis in Pediatric Hematology Patients. <i>Journal of the Pediatric Infectious Diseases Society</i> , 2012, 1, 103-111.	1.3	39
25	Comparative effectiveness of echinocandins versus fluconazole therapy for the treatment of adult candidaemia due to <i>Candida parapsilosis</i> : a retrospective observational cohort study of the Mycoses Study Group (MSG-12): Table A1. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 3536-3539.	3.0	37
26	Sorafenib in Combination With Standard Chemotherapy for Children With High Allelic Ratio <i>FLT3/ITD+</i> Acute Myeloid Leukemia: A Report From the Children's Oncology Group Protocol AAML1031. <i>Journal of Clinical Oncology</i> , 2022, 40, 2023-2035.	1.6	36
27	Poverty and Targeted Immunotherapy: Survival in Children's Oncology Group Clinical Trials for High-Risk Neuroblastoma. <i>Journal of the National Cancer Institute</i> , 2021, 113, 282-291.	6.3	33
28	Hospitalizations for Coccidioidomycosis at Forty-One Children's Hospitals in the United States. <i>Pediatric Infectious Disease Journal</i> , 2010, 29, 243-247.	2.0	32
29	Using electronic medical record data to report laboratory adverse events. <i>British Journal of Haematology</i> , 2017, 177, 283-286.	2.5	31
30	Risk factors for renal failure in pediatric patients with acute myeloid leukemia: A retrospective cohort study. <i>Pediatric Blood and Cancer</i> , 2010, 55, 655-661.	1.5	29
31	The role of acuity of illness at presentation in early mortality in black children with acute myeloid leukemia. <i>American Journal of Hematology</i> , 2017, 92, 141-148.	4.1	29
32	Invasive Fungal Disease in Pediatric Solid Organ Transplant Recipients. <i>Journal of the Pediatric Infectious Diseases Society</i> , 2018, 7, 219-225.	1.3	28
33	The Effectiveness Of Government Masking Mandates On COVID-19 County-Level Case Incidence Across The United States, 2020. <i>Health Affairs</i> , 2022, 41, 445-453.	5.2	27
34	Caspofungin for the Treatment of Pediatric Fungal Infections. <i>Pediatric Infectious Disease Journal</i> , 2008, 27, 1099-1102.	2.0	25
35	Association of Weekend Admission With Hospital Length of Stay, Time to Chemotherapy, and Risk for Respiratory Failure in Pediatric Patients With Newly Diagnosed Leukemia at Freestanding US Children's Hospitals. <i>JAMA Pediatrics</i> , 2014, 168, 925.	6.2	24
36	Suspected posaconazole toxicity in a pediatric oncology patient. <i>Pediatric Blood and Cancer</i> , 2015, 62, 1682-1682.	1.5	24

#	ARTICLE	IF	CITATIONS
37	American Society of Transplantation and Cellular Therapy Series, 2: Management and Prevention of Aspergillosis in Hematopoietic Cell Transplantation Recipients. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 201-211.	1.2	23
38	<i>Staphylococcus aureus</i> Bacteremia in Hospitalized Children: Incidence and Outcomes. <i>Infection Control and Hospital Epidemiology</i> , 2015, 36, 603-605.	1.8	22
39	Variation in hospital antibiotic prescribing practices for children with acute lymphoblastic leukemia. <i>Leukemia and Lymphoma</i> , 2013, 54, 1633-1639.	1.3	21
40	Comparison of in-patient costs for children treated on the AAML0531 clinical trial: A report from the Children's Oncology Group. <i>Pediatric Blood and Cancer</i> , 2015, 62, 1775-1781.	1.5	21
41	Disparities in pediatric acute myeloid leukemia (AML) clinical trial enrollment. <i>Leukemia and Lymphoma</i> , 2019, 60, 2190-2198.	1.3	21
42	A Randomized Trial of Caspofungin vs Triazoles Prophylaxis for Invasive Fungal Disease in Pediatric Allogeneic Hematopoietic Cell Transplant. <i>Journal of the Pediatric Infectious Diseases Society</i> , 2021, 10, 417-425.	1.3	19
43	Sorafenib in Combination with Standard Chemotherapy for Children with High Allelic Ratio FLT3/ITD+ AML Improves Event-Free Survival and Reduces Relapse Risk: A Report from the Children's Oncology Group Protocol AAML1031. <i>Blood</i> , 2019, 134, 292-292.	1.4	19
44	Variation in Risk of Hospital-Onset <i>Clostridium difficile</i> Infection Across β -Lactam Antibiotics in Children With New-Onset Acute Lymphoblastic Leukemia. <i>Journal of the Pediatric Infectious Diseases Society</i> , 2014, 3, 329-335.	1.3	18
45	Administration and Dosing of Systemic Antifungal Agents in Pediatric Patients. <i>Paediatric Drugs</i> , 2020, 22, 165-188.	3.1	18
46	A comparison of resource utilization following chemotherapy for acute myeloid leukemia in children discharged versus children that remain hospitalized during neutropenia. <i>Cancer Medicine</i> , 2015, 4, 1356-1364.	2.8	17
47	Opioid utilization among pediatric patients treated for newly diagnosed acute myeloid leukemia. <i>PLoS ONE</i> , 2018, 13, e0192529.	2.5	16
48	Broad-Spectrum Antibiotics and Risk of Graft-versus-Host Disease in Pediatric Patients Undergoing Transplantation for Acute Leukemia: Association of Carbapenem Use with the Risk of Acute Graft-versus-Host Disease. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 177.e1-177.e8.	1.2	16
49	Merging Children's Oncology Group Data with an External Administrative Database Using Indirect Patient Identifiers: A Report from the Children's Oncology Group. <i>PLoS ONE</i> , 2015, 10, e0143480.	2.5	16
50	Establishing a high-risk neuroblastoma cohort using the pediatric health information system database. <i>Pediatric Blood and Cancer</i> , 2014, 61, 1129-1131.	1.5	15
51	A quality improvement initiative to increase pneumococcal vaccination coverage among children after kidney transplant. <i>Pediatric Transplantation</i> , 2016, 20, 783-789.	1.0	15
52	Dexrazoxane Use in Pediatric Patients with Acute Lymphoblastic or Myeloid Leukemia: Analysis of a National Cohort of Patients in the Pediatric Health Information Systems Database From 1999 to 2009. <i>Blood</i> , 2011, 118, 4242-4242.	1.4	15
53	Treatment of Invasive Candidiasis in Immunocompromised Pediatric Patients. <i>Paediatric Drugs</i> , 2008, 10, 281-298.	3.1	14
54	Supportive care utilization and treatment toxicity in children with Down syndrome and acute lymphoid leukaemia at free-standing paediatric hospitals in the United States. <i>British Journal of Haematology</i> , 2016, 174, 591-599.	2.5	14

#	ARTICLE	IF	CITATIONS
55	Chlorhexidine gluconate bathing in children with cancer or those undergoing hematopoietic stem cell transplantation: A double-blind randomized controlled trial from the Children's Oncology Group. <i>Cancer</i> , 2021, 127, 56-66.	4.1	14
56	Prospective Evaluation of Galactomannan and (1 α 3)-D-Glucan Assays as Diagnostic Tools for Invasive Fungal Disease in Children, Adolescents, and Young Adults With Acute Myeloid Leukemia Receiving Fungal Prophylaxis. <i>Journal of the Pediatric Infectious Diseases Society</i> , 2021, 10, 864-871.	1.3	14
57	Cefepime and Mortality in Pediatric Acute Myelogenous Leukemia. <i>Pediatric Infectious Disease Journal</i> , 2009, 28, 971-975.	2.0	13
58	The Role of Biomarkers for Diagnosis of and Therapeutic Decisions Related to Invasive Aspergillosis in Children. <i>Current Fungal Infection Reports</i> , 2013, 7, 7-14.	2.6	13
59	A comparison of discharge strategies after chemotherapy completion in pediatric patients with acute myeloid leukemia: a report from the Children's Oncology Group. <i>Leukemia and Lymphoma</i> , 2016, 57, 1567-1574.	1.3	13
60	Cost comparison by treatment arm and center-level variations in cost and inpatient days on the phase III high-risk B acute lymphoblastic leukemia trial AALL0232. <i>Cancer Medicine</i> , 2018, 7, 3-12.	2.8	13
61	Comparison of administrative/billing data to expected protocol-mandated chemotherapy exposure in children with acute myeloid leukemia: A report from the Children's Oncology Group. <i>Pediatric Blood and Cancer</i> , 2015, 62, 1184-1189.	1.5	12
62	Treatment of Osteonecrosis in Children and Adolescents With Acute Lymphoblastic Leukemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2016, 16, 223-229.e2.	0.4	12
63	Human Adenovirus 7-Associated Hemophagocytic Lymphohistiocytosis-like Illness: Clinical and Virological Characteristics in a Cluster of Five Pediatric Cases. <i>Clinical Infectious Diseases</i> , 2021, 73, e1532-e1538.	5.8	12
64	Epidemiology and potential preventative measures for viral infections in children with malignancy and those undergoing hematopoietic cell transplantation. <i>Pediatric Blood and Cancer</i> , 2012, 59, 11-15.	1.5	11
65	Induction mortality, ATRA administration, and resource utilization in a nationally representative cohort of children with acute promyelocytic leukemia in the United States from 1999 to 2009. <i>Pediatric Blood and Cancer</i> , 2014, 61, 68-73.	1.5	11
66	Volume-Outcome Relationships in Pediatric Acute Lymphoblastic Leukemia: Association Between Hospital Pediatric and Pediatric Oncology Volume With Mortality and Intensive Care Resources During Initial Therapy. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2016, 16, 404-410.e1.	0.4	11
67	Identification of a novel intertypic recombinant species D human adenovirus in a pediatric stem cell transplant recipient. <i>Journal of Clinical Virology</i> , 2014, 61, 496-502.	3.1	10
68	Hospital Variation in Intensive Care Resource Utilization and Mortality in Newly Diagnosed Pediatric Leukemia*. <i>Pediatric Critical Care Medicine</i> , 2018, 19, e312-e320.	0.5	10
69	Diagnostic Challenges in Pediatric Hemophagocytic Lymphohistiocytosis. <i>Journal of Clinical Immunology</i> , 2021, 41, 1213-1218.	3.8	10
70	Multicenter Prospective Study of Biomarkers for Diagnosis of Invasive Candidiasis in Children and Adolescents. <i>Clinical Infectious Diseases</i> , 2022, 75, 248-259.	5.8	10
71	Pediatric Risk Factors for Candidemia Secondary to <i>Candida glabrata</i> and <i>Candida krusei</i> Species. <i>Journal of the Pediatric Infectious Diseases Society</i> , 2013, 2, 263-266.	1.3	8
72	Resource Utilization and Toxicities After Carboplatin/Etoposide/Melphalan and Busulfan/Melphalan for Autologous Stem Cell Rescue in High-Risk Neuroblastoma Using a National Administrative Database. <i>Pediatric Blood and Cancer</i> , 2016, 63, 901-907.	1.5	8

#	ARTICLE	IF	CITATIONS
73	Low rates of pregnancy screening in adolescents before teratogenic exposures in a national sample of children's hospitals. <i>Cancer</i> , 2016, 122, 3394-3400.	4.1	8
74	Retrospective review of immunocompromised children undergoing skin biopsy for suspected invasive infection: Analysis of factors predictive of invasive mold. <i>Pediatric Dermatology</i> , 2018, 35, 104-111.	0.9	8
75	A multicenter study to define the epidemiology and outcomes of <i>Clostridioides difficile</i> infection in pediatric hematopoietic cell and solid organ transplant recipients. <i>American Journal of Transplantation</i> , 2020, 20, 2133-2142.	4.7	8
76	Early stool microbiome and metabolome signatures in pediatric patients undergoing allogeneic hematopoietic cell transplantation. <i>Pediatric Blood and Cancer</i> , 2022, 69, e29384.	1.5	8
77	Challenges in the Treatment of Invasive Aspergillosis in Immunocompromised Children. <i>Antimicrobial Agents and Chemotherapy</i> , 2022, 66, .	3.2	8
78	Burden of Influenza-Related Hospitalizations and Attributable Mortality in Pediatric Acute Lymphoblastic Leukemia. <i>Journal of the Pediatric Infectious Diseases Society</i> , 2015, 4, 290-296.	1.3	7
79	Comparative effectiveness of fungicidal vs. fungistatic therapies for the treatment of paediatric candidaemia. <i>Mycoses</i> , 2016, 59, 173-178.	4.0	7
80	Outcomes of human adenovirus infection and disease in a retrospective cohort of pediatric solid organ transplant recipients. <i>Pediatric Transplantation</i> , 2019, 23, e13510.	1.0	7
81	Identifying patient- and family-centered outcomes relevant to inpatient versus at-home management of neutropenia in children with acute myeloid leukemia. <i>Pediatric Blood and Cancer</i> , 2018, 65, e26927.	1.5	6
82	Hospital-Level Variability in Broad-Spectrum Antibiotic Use for Children With Acute Leukemia Undergoing Hematopoietic Cell Transplantation. <i>Infection Control and Hospital Epidemiology</i> , 2018, 39, 797-805.	1.8	6
83	Fatal Neonatal Sepsis Associated with Human Adenovirus Type 56 Infection: Genomic Analysis of Three Recent Cases Detected in the United States. <i>Viruses</i> , 2021, 13, 1105.	3.3	6
84	Medical Outcomes, Quality of Life, and Family Perceptions for Outpatient vs Inpatient Neutropenia Management After Chemotherapy for Pediatric Acute Myeloid Leukemia. <i>JAMA Network Open</i> , 2021, 4, e2128385.	5.9	6
85	Bortezomib Inpatient Prescribing Practices in Free-Standing Children's Hospitals in the United States. <i>PLoS ONE</i> , 2016, 11, e0151362.	2.5	5
86	Creation of a pediatric mature B-cell non-Hodgkin lymphoma cohort within the Pediatric Health Information System Database. <i>PLoS ONE</i> , 2017, 12, e0186960.	2.5	5
87	Complete Versus Staged Repair for Neonates With Tetralogy of Fallot. <i>Medical Care</i> , 2018, 56, e76-e82.	2.4	5
88	Posaconazole Administration in Hospitalized Children in the United States. <i>Journal of the Pediatric Infectious Diseases Society</i> , 2019, 8, 481-484.	1.3	5
89	Effect of first-line biologic initiation on glucocorticoid exposure in children hospitalized with new-onset systemic juvenile idiopathic arthritis: emulation of a pragmatic trial using observational data. <i>Pediatric Rheumatology</i> , 2021, 19, 109.	2.1	5
90	Pneumocystis Pneumonia: Epidemiology and Options for Prophylaxis in Non-HIV Immunocompromised Pediatric Patients. <i>Current Fungal Infection Reports</i> , 2014, 8, 45-55.	2.6	4

#	ARTICLE	IF	CITATIONS
91	Early discharge as a mediator of greater ICU-level care requirements in patients not enrolled on the AAML0531 clinical trial: a Children's Oncology Group report. <i>Cancer Medicine</i> , 2016, 5, 2412-2416.	2.8	4
92	Complications preceding early deaths in Black and White children with acute myeloid leukemia. <i>Pediatric Blood and Cancer</i> , 2017, 64, e26712.	1.5	4
93	Center-level variation in accuracy of adverse event reporting in a clinical trial for pediatric acute myeloid leukemia: a report from the Children's Oncology Group. <i>Haematologica</i> , 2017, 102, e340-e343.	3.5	4
94	Resource utilization and toxicities after single versus tandem autologous stem cell rescue in high-risk neuroblastoma using a national administrative database. <i>Pediatric Blood and Cancer</i> , 2018, 65, e27372.	1.5	4
95	Impact of Trimethoprim-sulfamethoxazole Urinary Tract Infection Prophylaxis on Non-UTI Infections. <i>Pediatric Infectious Disease Journal</i> , 2019, 38, 396-397.	2.0	4
96	The epidemiology of rasburicase use in paediatric patients with acute lymphoblastic leukaemia and non-Hodgkin lymphoma. <i>British Journal of Haematology</i> , 2019, 184, 684-688.	2.5	4
97	Variation in treatment of children hospitalized with new-onset systemic juvenile idiopathic arthritis in the United States. <i>Arthritis Care and Research</i> , 2020, 73, 1714-1721.	3.4	4
98	Musculoskeletal impairments in children receiving intensive therapy for acute leukemia or undergoing hematopoietic stem cell transplant: A report from the Children's Oncology Group. <i>Pediatric Blood and Cancer</i> , 2021, 68, e29053.	1.5	4
99	Center Variability in Acute Rejection and Biliary Complications After Pediatric Liver Transplantation. <i>Liver Transplantation</i> , 2022, 28, 454-465.	2.4	4
100	Incidence and risk factors for hypoglycemia during maintenance chemotherapy in pediatric acute lymphoblastic leukemia. <i>Pediatric Blood and Cancer</i> , 2022, 69, e29467.	1.5	4
101	International Collaborative on Contemporary Epidemiology and Diagnosis of Invasive Fungal Disease in Children. <i>Journal of the Pediatric Infectious Diseases Society</i> , 2017, 6, S1-S2.	1.3	3
102	Successful treatment of pulmonary mucormycosis in two pediatric hematopoietic stem cell transplant patients. <i>Pediatric Transplantation</i> , 2018, 22, e13270.	1.0	3
103	Comparative Effectiveness of Echinocandins vs Triazoles or Amphotericin B Formulations as Initial Directed Therapy for Invasive Candidiasis in Children and Adolescents. <i>Journal of the Pediatric Infectious Diseases Society</i> , 2021, , .	1.3	3
104	Rates of Laboratory Adverse Events By Chemotherapy Course for Pediatric Acute Leukemia Patients within the Leukemia Electronic Abstraction of Records Network (LEARN). <i>Blood</i> , 2019, 134, 333-333.	1.4	3
105	Evaluation of resources used during care of children with high-risk neuroblastoma (HR NBL) via merging of cooperative group trial data and administrative data.. <i>Journal of Clinical Oncology</i> , 2014, 32, 10069-10069.	1.6	3
106	Increased Disease Burden Among Black Children Compared to White Children with Newly Diagnosed Acute Myeloid Leukemia. <i>Blood</i> , 2018, 132, 369-369.	1.4	3
107	Administration of Palivizumab in the NICU. <i>Hospital Pediatrics</i> , 2016, 6, 354-358.	1.3	2
108	The Changing Landscape for Paediatric Regulation of Pharmaceutical Agents with a Focus on Antifungal Agents. <i>Current Fungal Infection Reports</i> , 2016, 10, 1-6.	2.6	2

#	ARTICLE	IF	CITATIONS
109	The Cost of Vancomycin and Piperacillin/Tazobactam Treatmentâ€™Reply. JAMA Pediatrics, 2018, 172, 494.	6.2	2
110	Evaluation of Hospital Admission Patterns in Children Receiving Treatment for Acute Lymphoblastic Leukemia: What Does a Typical Leukemia Experience Look like?. Blood, 2018, 132, 4763-4763.	1.4	2
111	Evolution of SARS-CoV-2 Seroprevalence Among Employees of a United States Academic Childrenâ€™s Hospital During the COVID-19 Pandemic. Infection Control and Hospital Epidemiology, 2021, , 1-24.	1.8	2
112	Antibiotic use in pediatric patients admitted to a referral hospital in Botswana. American Journal of Tropical Medicine and Hygiene, 2009, 81, 129-31.	1.4	2
113	1074Immunization Practices of Pediatric Oncology Providers Towards Children with Acute Lymphoblastic Leukemia that have Completed Chemotherapy. Open Forum Infectious Diseases, 2014, 1, S315-S315.	0.9	1
114	Infectious diseases approach to immunocompromised patients in the pediatric intensive care unit. Journal of Pediatric Intensive Care, 2015, 03, 305-313.	0.8	1
115	Conventional compared to network meta-analysis to evaluate antibiotic prophylaxis in patients with cancer and haematopoietic stem cell transplantation recipients. BMJ Evidence-Based Medicine, 2020, 26, bmjebm-2020-111362.	3.5	1
116	Presentation acuity, induction mortality, and resource utilization in infants with acute leukemia. Pediatric Blood and Cancer, 2021, 68, e28940.	1.5	1
117	Area-Based Socioeconomic Disparities in Survival of Children with Newly Diagnosed Acute Myeloid Leukemia: A Report from the Children's Oncology Group. Blood, 2019, 134, 703-703.	1.4	1
118	Avascular Necrosis(AVN) and Surgical Intervention In Pediatric Acute Lymphoblastic Leukemia(ALL): A Retrospective Cohort Analysis From The Pediatric Health Information Systems (PHIS). Blood, 2013, 122, 1689-1689.	1.4	1
119	Accuracy Of Adverse Event Reporting Compared To Patient Chart Abstraction On a Phase III NCI-Funded Clinical Trial For Pediatric Acute Myeloid Leukemia: A Report From The Childrenâ€™s Oncology Group. Blood, 2013, 122, 931-931.	1.4	1
120	Poverty and survival in targeted immunotherapy clinical trials.. Journal of Clinical Oncology, 2019, 37, 10034-10034.	1.6	1
121	Induction Mortality In Pediatric Acute Lymphoblastic Leukemia (ALL): a Retrospective Cohort Analysis From the Pediatric Health Systems Information (PHIS) Database, 1999â€™2009. Blood, 2010, 116, 3239-3239.	1.4	1
122	Treatment Toxicity and Supportive Care Utilization in Children with Down Syndrome and Acute Lymphoid Leukemia at Free-Standing Pediatric Hospitals in the United States. Blood, 2014, 124, 553-553.	1.4	1
123	Home or Away from Home: A Multi-Institution Study Comparing Medical Outcomes, Patient Perspectives, and Health-Related Quality of Life for Outpatient Versus Inpatient Management after Chemotherapy for Pediatric Acute Myeloid Leukemia. Blood, 2019, 134, 379-379.	1.4	1
124	Assessment of the impact of inpatient infectious events in pediatric patients with newly diagnosed acute leukemia at Dr. Robert Reid Cabral Childrenâ€™s Hospital, Dominican Republic. PLoS ONE, 2020, 15, e0243795.	2.5	1
125	Center Variation in Indication and Short-Term Outcomes after Pediatric Heart Transplantation: Analysis of a Merged United Network for Organ Sharing â€™ Pediatric Health Information System Cohort. Pediatric Cardiology, 2022, 43, 636-644.	1.3	1
126	Risk of bacterial bloodstream infection does not vary by central-line type during neutropenic periods in pediatric acute myeloid leukemia. Infection Control and Hospital Epidemiology, 2023, 44, 222-229.	1.8	1

#	ARTICLE	IF	CITATIONS
127	1444Comparative effectiveness of fungicidal vs fungistatic therapies for the treatment of pediatric candidemia. Open Forum Infectious Diseases, 2014, 1, S380-S380.	0.9	0
128	Management of invasive fungal infections in the pediatric intensive care unit. Journal of Pediatric Intensive Care, 2015, 03, 269-279.	0.8	0
129	A marginal structural approach to measuring the comparative effectiveness of echinocandins Versus fluconazole therapy for the treatment of adult candidemia (MSG-12). Open Forum Infectious Diseases, 2016, 3, .	0.9	0
130	Prophylaxis Against Invasive Fungal Disease for Neutropenic Children and Young Adultsâ€™Reply. JAMA - Journal of the American Medical Association, 2020, 323, 998.	7.4	0
131	Merging of Children's Oncology Group and Pediatric Health Information Systems Data to Determine Resource Utilization and Treatment Costs on AAML0531: A Report From the Children's Oncology Group. Blood, 2011, 118, 2617-2617.	1.4	0
132	Dexrazoxane exposure and risk of secondary acute myeloid leukemia in pediatric cancer patients.. Journal of Clinical Oncology, 2012, 30, 1504-1504.	1.6	0
133	Mortality and Resource Utilization in Children with De Novo Acute Myeloid Leukemia Treated with Chemotherapy and Gemtuzumab Ozogamicin in the United States. Blood, 2012, 120, 4283-4283.	1.4	0
134	Variation in antibiotic use in pediatric acute lymphoblastic leukemia (ALL) by hospital pediatric volume.. Journal of Clinical Oncology, 2014, 32, e17703-e17703.	1.6	0
135	Impact of weekend admission on hospital length of stay and organ failure in pediatric leukemia patients at free-standing U.S. childrenâ€™s hospitals.. Journal of Clinical Oncology, 2014, 32, 6598-6598.	1.6	0
136	Standardized costs and outcome in children treated with gemtuzumab on the AAML0531 trial: A report from the Childrenâ€™s Oncology Group.. Journal of Clinical Oncology, 2014, 32, 7086-7086.	1.6	0
137	Broncho-Alveolar Lavage and Lung Biopsy in Patients with Hematological Malignancy and Hematopoietic Stem Cell Transplantation Recipients: A Systematic Review and Meta-Analysis. Blood, 2014, 124, 2628-2628.	1.4	0
138	ÂResource Utilization and Cost Analysis By Treatment Arm on the Childrenâ€™s Oncology Group AALL0232 Phase 3 High-Risk B-Precursor Acute Lymphoblastic Leukemia Trial: A Report from the Childrenâ€™s Oncology Group. Blood, 2014, 124, 210-210.	1.4	0
139	Accuracy of adverse event reporting on a phase III clinical trial for pediatric acute myeloid leukemia: A report from the Childrenâ€™s Oncology Group.. Journal of Clinical Oncology, 2015, 33, 10028-10028.	1.6	0
140	Resource utilization (RU) and toxicities after carboplatin/etoposide/melphalan (CEM) and busulfan/melphalan (BuMel) for autologous stem cell rescue (ASCR) in high-risk neuroblastoma (HRNB).. Journal of Clinical Oncology, 2015, 33, e21009-e21009.	1.6	0
141	Racial Disparities in Pediatric Acute Myeloid Leukemia during Induction. Blood, 2015, 126, 530-530.	1.4	0
142	Using administrative laboratory result data to describe adverse events.. Journal of Clinical Oncology, 2018, 36, e18698-e18698.	1.6	0
143	Assessing Neighborhood Characteristics As Risk Factors for Bloodstream Infection in Children with Acute Leukemia. Blood, 2018, 132, 833-833.	1.4	0
144	Using Administrative Data to Identify Relapse and Hematopoietic Stem Cell Transplantation (HSCT) in Children with Acute Lymphoblastic Leukemia (ALL): Validation at Two Centers and Incidence Estimation in a National Cohort. Blood, 2018, 132, 624-624.	1.4	0

#	ARTICLE	IF	CITATIONS
145	A Novel Approach to Identifying Septic Shock (SS) in Children with Acute Lymphoblastic Leukemia (ALL) Using Pediatric Health Information System (PHIS) Data: Methods Validation and Incidence Estimation in a National Cohort. Blood, 2018, 132, 3597-3597.	1.4	0
146	Comparative Effectiveness of Rasburicase and Allopurinol in Children with Acute Lymphoblastic Leukemia: An Emulated Pragmatic Trial Using Observational Data. Blood, 2018, 132, 830-830.	1.4	0
147	1745. Retrospective Cohort Analysis to Determine the Incidence of CMV Infection and Disease in Allogeneic Hematopoietic Cell Transplant Recipients at an Academic Children's Hospital. Open Forum Infectious Diseases, 2019, 6, S639-S640.	0.9	0
148	Reduced Relapse Risk in Children with Acute Myeloid Leukemia (AML) Who Experience Septic Shock (SS). Blood, 2019, 134, 3496-3496.	1.4	0
149	Fungal diagnostic testing and therapy: navigating the neutropenic period in children with high-risk leukemia. Hematology American Society of Hematology Education Program, 2021, 2021, 361-367.	2.5	0